Independent directory Public ClinicalTrials.gov records United States
Clinical Trials Finder
Objective public record navigation
Search Results

Search by objective public record fields.

Search by query text, NCT ID, condition, intervention, sponsor, city, state, recruitment status, phase, study type, healthy volunteer eligibility, sex, or age. Results come from ClinicalTrials.gov. When the live registry is unavailable, a clearly labeled stored copy may be shown.

Clear filters

These results were retrieved from the live ClinicalTrials.gov registry. Filters and sort order apply to this result list.

ClinicalTrials.gov public records Last synced Oct 24, 2026, 5:21 AM EDT

Data is sourced from official ClinicalTrials.gov public API records. Always review the official ClinicalTrials.gov record for the latest information.

Showing 1009–1032 of 21,205 matching trials from the live ClinicalTrials.gov search.
Filters: Condition: Immunity Disorders Clear all
Completed Phase 1 Interventional

Vorinostat With Gemcitabine, Busulfan, and Melphalan With Stem Cell Transplant (SCT) in Relapsed or Refractory Lymphoid Malignancies

NCT01421173
View directory record Official record
Conditions
Lymphoma
Interventions
Vorinostat, Gemcitabine, Busulfan, Melphalan, Stem Cell Infusion, Rituximab, G-CSF, Palifermin, Dexamethasone acetate
Drug · Procedure
Lead sponsor
M.D. Anderson Cancer Center
Other
Eligibility
12 Years to 65 Years
Enrollment
78 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2011 – 2015
U.S. locations
1
States / cities
Houston, Texas
Source: ClinicalTrials.gov public record
Updated Nov 18, 2015 · Synced Oct 24, 2026, 5:21 AM EDT
Recruiting Phase 4 Interventional

Modeling Ketosis-Prone Diabetes Remission Via Diverse Mechanisms of Glucotoxicity

NCT06699810
View directory record Official record
Conditions
Ketosis Prone Diabetes
Interventions
Continuous Glucose Monitoring, Insulin
Device · Drug
Lead sponsor
Emory University
Other
Eligibility
18 Years and older
Enrollment
12 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2025 – 2027
U.S. locations
2
States / cities
Atlanta, Georgia
Source: ClinicalTrials.gov public record
Updated Jun 15, 2026 · Synced Oct 24, 2026, 5:21 AM EDT
Terminated Phase 2 Interventional Results available

Study of Apremilast to Evaluate the Safety and Effectiveness for Patients With Rheumatoid Arthritis

NCT01285310
View directory record Official record
Conditions
Rheumatoid Arthritis
Interventions
Apremilast 30 mg, Apremilast 20 mg, Placebo
Drug
Lead sponsor
Amgen
Industry
Eligibility
18 Years and older
Enrollment
237 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2010 – 2012
U.S. locations
29
States / cities
Gilbert, Arizona • Phoenix, Arizona • La Mesa, California + 23 more
Source: ClinicalTrials.gov public record
Updated May 8, 2020 · Synced Oct 24, 2026, 5:21 AM EDT
Terminated Phase 2 Interventional Results available

SOLAR: Efficacy and Safety of Cobomarsen (MRG-106) vs. Active Comparator in Subjects With Mycosis Fungoides

NCT03713320
View directory record Official record
Conditions
Cutaneous T-Cell Lymphoma/Mycosis Fungoides
Interventions
Cobomarsen, Vorinostat
Drug
Lead sponsor
miRagen Therapeutics, Inc.
Industry
Eligibility
18 Years and older
Enrollment
37 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2019 – 2020
U.S. locations
20
States / cities
Birmingham, Alabama • Phoenix, Arizona • Duarte, California + 16 more
Source: ClinicalTrials.gov public record
Updated Apr 8, 2022 · Synced Oct 24, 2026, 5:21 AM EDT
Recruiting Phase 3 Interventional

A Study to Compare Linvoseltamab and Daratumumab Treatment in High-Risk Smoldering Multiple Myeloma (HR-SMM)

NCT07393282
View directory record Official record
Conditions
High Risk Smoldering Multiple Myeloma (HR-SMM)
Interventions
Linvoseltamab, Daratumumab
Drug
Lead sponsor
Regeneron Pharmaceuticals
Industry
Eligibility
18 Years and older
Enrollment
270 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2026 – 2033
U.S. locations
9
States / cities
Phoenix, Arizona • Atlanta, Georgia • Boston, Massachusetts + 5 more
Source: ClinicalTrials.gov public record
Updated Oct 21, 2026 · Synced Oct 24, 2026, 5:21 AM EDT
Completed Phase 2 Interventional Results available

Safety and Efficacy Study of R932348 Ophthalmic Solution in Chronic Ocular Graft Versus Host Disease Patients(DROPS-2)

NCT02040623
View directory record Official record
Conditions
Chronic Graft-versus-host Disease
Interventions
R348 Ophthalmic Solution, 0.2%, R348 Ophthalmic Solution, 0.5%, Placebo Ophthalmic Solution
Drug · Other
Lead sponsor
Rigel Pharmaceuticals
Industry
Eligibility
18 Years to 85 Years
Enrollment
35 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2014 – 2016
U.S. locations
2
States / cities
Plantation, Florida • Boston, Massachusetts
Source: ClinicalTrials.gov public record
Updated Oct 10, 2016 · Synced Oct 24, 2026, 5:21 AM EDT
Completed Phase 2 Interventional

A Study to Compare Two Anti-HIV Drug Combinations That Include Amprenavir in HIV-Infected Patients Who Have Failed Anti-HIV Drug Combinations That Did Not Include Amprenavir

NCT00002423
View directory record Official record
Conditions
HIV Infections
Interventions
Indinavir sulfate, Abacavir sulfate, Amprenavir, Nelfinavir mesylate, Lamivudine
Drug
Lead sponsor
Glaxo Wellcome
Industry
Eligibility
13 Years and older
Enrollment
100 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
Started 1999
U.S. locations
8
States / cities
San Francisco, California • Washington D.C., District of Columbia • Altamonte Springs, Florida + 5 more
Source: ClinicalTrials.gov public record
Updated Jun 24, 2005 · Synced Oct 24, 2026, 5:21 AM EDT
Withdrawn Phase 3 Interventional

Gan & Lee Evaluation of New Biosimilar for Type 1 Lispro

NCT04254380
View directory record Official record
Conditions
Diabetes Mellitus, Type 1
Interventions
Gan & Lee Insulin Lispro Injection, Humalog
Biological
Lead sponsor
Gan and Lee Pharmaceuticals, USA
Industry
Eligibility
18 Years to 75 Years
Healthy volunteers
Healthy volunteers not accepted
Timeline
2019 – 2020
U.S. locations
58
States / cities
Anaheim, California • Fresno, California • Los Angeles, California + 52 more
Source: ClinicalTrials.gov public record
Updated Feb 5, 2020 · Synced Oct 24, 2026, 5:21 AM EDT
Completed Phase 2 Interventional Results available

CINJALL: Treatment for Children With Acute Lymphocytic Leukemia

NCT00176462
View directory record Official record
Conditions
Acute Lymphocytic Leukemia
Interventions
aminopterin, L-asparaginase, cyclophosphamide, cytarabine, daunomycin, dexamethasone, 6-mercaptopurine, methotrexate, 6-thioguanine, vincristine, Triple Intrathecal Therapy (MTX, Cytarabine, Hydrocortisone), Leucovorin
Drug
Lead sponsor
Rutgers, The State University of New Jersey
Other
Eligibility
1 Year to 30 Years
Enrollment
60 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2001 – 2008
U.S. locations
2
States / cities
Neptune City, New Jersey • New Brunswick, New Jersey
Source: ClinicalTrials.gov public record
Updated Jun 9, 2014 · Synced Oct 24, 2026, 5:21 AM EDT
Not yet recruiting No phase listed Observational

Effect of Acetominophen an Gait Fatigue in Multiple Sclerosis

NCT07440446
View directory record Official record
Conditions
Multiple Sclerosis
Interventions
1000mg acetaminophen or placebo
Drug
Lead sponsor
Hunter College of City University of New York
Other
Eligibility
18 Years to 65 Years
Enrollment
20 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2026
U.S. locations
1
States / cities
New York, New York
Source: ClinicalTrials.gov public record
Updated Mar 17, 2026 · Synced Oct 24, 2026, 5:21 AM EDT
Completed Phase 1 Interventional Accepts healthy volunteers

A Study to Investigate the Safety, Tolerability and Pharmacokinetics of Repeat Dose Administration of Long-Acting GSK1265744 and Long-Acting TMC278 Intramuscular and Subcutaneous Injections in Healthy Adult Subjects

NCT01593046
View directory record Official record
Conditions
Infection, Human Immunodeficiency Virus
Interventions
GSK1265744 Oral, GSK1265744 LAP 800mg intramuscular injection, GSK1265744 LAP 200mg subcutaneous injection, GSK1265744 LAP 200mg intramuscular injection, GSK1265744 LAP 400mg intramuscular injection, TMC278 LA 1200mg intramuscular injection, TMC278 LA 600mg intramuscular injection
Drug
Lead sponsor
ViiV Healthcare
Industry
Eligibility
18 Years to 64 Years
Enrollment
43 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2012 – 2013
U.S. locations
2
States / cities
Daytona Beach, Florida • Overland Park, Kansas
Source: ClinicalTrials.gov public record
Updated Feb 10, 2014 · Synced Oct 24, 2026, 5:21 AM EDT
Completed Phase 1Phase 2 Interventional Results available

Autologous Stem Cell Transplant Followed by Donor Stem Cell Transplant in Treating Patients With Relapsed or Refractory Lymphoma

NCT00005803
View directory record Official record
Conditions
Prolymphocytic Leukemia, Recurrent Adult Hodgkin Lymphoma, Recurrent Childhood Hodgkin Lymphoma, Recurrent Childhood Non-Hodgkin Lymphoma, Recurrent Chronic Lymphocytic Leukemia, Recurrent Non-Hodgkin Lymphoma, Recurrent Small Lymphocytic Lymphoma, Refractory Childhood Hodgkin Lymphoma, Refractory Chronic Lymphocytic Leukemia, Refractory Hodgkin Lymphoma, Refractory Non-Hodgkin Lymphoma, Refractory Small Lymphocytic Lymphoma, T-Cell Chronic Lymphocytic Leukemia, T-Cell Prolymphocytic Leukemia
Interventions
Autologous Hematopoietic Stem Cell Transplantation, Autologous-Allogeneic Tandem Hematopoietic Stem Cell Transplantation, Carmustine, Cyclophosphamide, Cyclosporine, Cytarabine, Etoposide, Fludarabine Phosphate, Laboratory Biomarker Analysis, Melphalan, Mycophenolate Mofetil, Nonmyeloablative Allogeneic Hematopoietic Stem Cell Transplantation, Peripheral Blood Stem Cell Transplantation, Therapeutic Autologous Lymphocytes, Total-Body Irradiation
Procedure · Drug · Other + 2 more
Lead sponsor
Fred Hutchinson Cancer Center
Other
Eligibility
Up to 75 Years
Enrollment
76 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
1999 – 2018
U.S. locations
4
States / cities
Salt Lake City, Utah • Seattle, Washington
Source: ClinicalTrials.gov public record
Updated Jan 29, 2020 · Synced Oct 24, 2026, 5:21 AM EDT
Terminated Phase 2 Interventional Results available

Dose Ranging Study of Brentuximab Vedotin in Adults With Lupus

NCT02533570
View directory record Official record
Conditions
Systemic Lupus Erythematosus
Interventions
Brentuximab vedotin, Placebo
Drug
Lead sponsor
Seagen Inc.
Industry
Eligibility
18 Years and older
Enrollment
20 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2015 – 2017
U.S. locations
17
States / cities
Birmingham, Alabama • El Cajon, California • La Palma, California + 14 more
Source: ClinicalTrials.gov public record
Updated Jun 11, 2018 · Synced Oct 24, 2026, 5:21 AM EDT
Completed Phase 1Phase 2 Interventional

STI571 Plus Combination Chemotherapy in Treating Patients With Chronic Myelogenous Leukemia or Acute Lymphocytic Leukemia

NCT00015860
View directory record Official record
Conditions
Leukemia
Interventions
daunorubicin hydrochloride, imatinib mesylate, prednisone, vincristine sulfate
Drug
Lead sponsor
Jonsson Comprehensive Cancer Center
Other
Eligibility
18 Years and older
Healthy volunteers
Healthy volunteers not accepted
Timeline
2001 – 2003
U.S. locations
5
States / cities
Duarte, California • Los Angeles, California • Stanford, California + 2 more
Source: ClinicalTrials.gov public record
Updated Jun 24, 2013 · Synced Oct 24, 2026, 5:21 AM EDT
Completed Phase 1 Interventional

Yttrium Y 90 Basiliximab and Combination Chemotherapy Before Stem Cell Transplant in Treating Patients With Mature T-cell Non-Hodgkin Lymphoma

NCT02342782
View directory record Official record
Conditions
Mature T-Cell and NK-Cell Non-Hodgkin Lymphoma, Recurrent Mature T- and NK-Cell Non-Hodgkin Lymphoma, Refractory Mature T-Cell and NK-Cell Non-Hodgkin Lymphoma, Recurrent Cutaneous T-Cell Non-Hodgkin Lymphoma, Refractory Cutaneous T-Cell Non-Hodgkin Lymphoma
Interventions
Yttrium Y 90 Basiliximab, Carmustine, Etoposide, Cytarabine, Melphalan, Autologous Hematopoietic Stem Cell Transplantation, Laboratory Biomarker Analysis, Pharmacological Study
Biological · Drug · Procedure + 1 more
Lead sponsor
City of Hope Medical Center
Other
Eligibility
18 Years and older
Enrollment
20 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2020 – 2024
U.S. locations
1
States / cities
Duarte, California
Source: ClinicalTrials.gov public record
Updated Mar 20, 2025 · Synced Oct 24, 2026, 5:21 AM EDT
Completed Phase 3 Interventional

Efficacy Study of Single-Dose Levalbuterol Tartrate HFA MDI Vs Placebo in Subjects 18 Years and Older With EIB

NCT00268723
View directory record Official record
Conditions
Exercise-induced Bronchospasm
Interventions
Levalbuterol tartrate HFA MDI, Placebo
Drug
Lead sponsor
Sumitomo Pharma America, Inc.
Industry
Eligibility
18 Years and older
Enrollment
15 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2005 – 2006
U.S. locations
2
States / cities
Denver, Colorado • Burke, Virginia
Source: ClinicalTrials.gov public record
Updated Feb 22, 2012 · Synced Oct 24, 2026, 5:21 AM EDT
Completed No phase listed Observational

Study of Transfusion-Transmitted Infections

NCT00023023
View directory record Official record
Conditions
Viral Disease, Blood Donation, Transfusion-Transmitted Infections
Interventions
Not listed
Lead sponsor
National Institutes of Health Clinical Center (CC)
NIH
Eligibility
Not listed
Enrollment
1,771 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
Started 2002
U.S. locations
3
States / cities
Washington D.C., District of Columbia • Bethesda, Maryland
Source: ClinicalTrials.gov public record
Updated Oct 6, 2026 · Synced Oct 24, 2026, 5:21 AM EDT
Terminated Phase 1Phase 2 Interventional Results available

Lenalidomide, Ixazomib, and Rituximab as Front-Line Therapy for High Risk Indolent B-Cell Lymphoma

NCT02898259
View directory record Official record
Conditions
B Cell Lymphoma, Lymphoma
Interventions
Ixazomib, Lenalidomide, Rituximab
Drug
Lead sponsor
Brian Hill
Other
Eligibility
18 Years and older
Enrollment
19 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2017 – 2022
U.S. locations
2
States / cities
Cleveland, Ohio
Source: ClinicalTrials.gov public record
Updated Sep 26, 2022 · Synced Oct 24, 2026, 5:21 AM EDT
Completed Not applicable Interventional Results available

Post-bypass Prophylactic IVIG in Infants and Neonates

NCT02043379
View directory record Official record
Conditions
Hypogammaglobulinemia, Congenital Heart Disease
Interventions
IVIG, Placebo
Drug · Other
Lead sponsor
University of Alabama at Birmingham
Other
Eligibility
Up to 6 Months
Enrollment
50 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2014 – 2015
U.S. locations
1
States / cities
Birmingham, Alabama
Source: ClinicalTrials.gov public record
Updated Apr 13, 2017 · Synced Oct 24, 2026, 5:21 AM EDT
Terminated Early Phase 1 Interventional

Filgrastim in Treating Patients With Bortezomib-, Carfilzomib-, or IMID-Refractory Multiple Myeloma

NCT01537861
View directory record Official record
Conditions
Multiple Myeloma
Interventions
Filgrastim, Bortezomib, Carfilzomib, Dexamethasone, Cyclophosphamide, Thalidomide, Lenalidomide, Pomalidomide
Drug
Lead sponsor
Washington University School of Medicine
Other
Eligibility
18 Years and older
Enrollment
7 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2012 – 2014
U.S. locations
1
States / cities
St Louis, Missouri
Source: ClinicalTrials.gov public record
Updated Jan 26, 2015 · Synced Oct 24, 2026, 5:21 AM EDT
Completed Not applicable Interventional Results available

Promoting Resiliency Among Lymphoma Survivors: The 3RP-Lymphoma

NCT03212261
View directory record Official record
Conditions
Lymphoma
Interventions
3RP-Lymphoma
Behavioral
Lead sponsor
Massachusetts General Hospital
Other
Eligibility
18 Years to 64 Years
Enrollment
37 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2017 – 2018
U.S. locations
1
States / cities
Boston, Massachusetts
Source: ClinicalTrials.gov public record
Updated Nov 10, 2021 · Synced Oct 24, 2026, 5:21 AM EDT
Completed Phase 3 Interventional Accepts healthy volunteers Results available

Asthma Action at Erie Trial

NCT02481986
View directory record Official record
Conditions
Asthma, Children
Interventions
Community Health Worker, Certified asthma educator
Behavioral
Lead sponsor
University of Illinois at Chicago
Other
Eligibility
5 Years to 16 Years
Enrollment
223 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2015 – 2021
U.S. locations
1
States / cities
Chicago, Illinois
Source: ClinicalTrials.gov public record
Updated Dec 9, 2021 · Synced Oct 24, 2026, 5:21 AM EDT
Completed No phase listed Observational

Reproductive Health in Men and Women With Vasculitis

NCT02176070
View directory record Official record
Conditions
Giant Cell Arteritis, Takayasu's Arteritis, Polyarteritis Nodosa, Wegener's Granulomatosis, Microscopic Polyangiitis, Churg-Strauss Syndrome, Behcet's Disease, Kawasaki Disease, Henoch-schoenlein Purpura, Vasculitis, Central Nervous System, Drug-induced Necrotizing Vasculitis
Interventions
Not listed
Lead sponsor
University of South Florida
Other
Eligibility
18 Years and older
Enrollment
467 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2011 – 2012
U.S. locations
1
States / cities
Tampa, Florida
Source: ClinicalTrials.gov public record
Updated Jun 26, 2014 · Synced Oct 24, 2026, 5:21 AM EDT
Completed Phase 1 Interventional Accepts healthy volunteers

Safety of and Immune Response to an Experimental HIV Vaccine (VRC-HIVADV014-00-VP) in HIV Uninfected Adults

NCT00119873
View directory record Official record
Conditions
HIV Infections
Interventions
VRC-HIVADV014-00-VP
Biological
Lead sponsor
National Institute of Allergy and Infectious Diseases (NIAID)
NIH
Eligibility
18 Years to 50 Years · Female only
Enrollment
48 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
Ends 2006
U.S. locations
3
States / cities
San Francisco, California • Nashville, Tennessee • Seattle, Washington
Source: ClinicalTrials.gov public record
Updated Oct 14, 2021 · Synced Oct 24, 2026, 5:21 AM EDT